Company Overview of Vitae Pharmaceuticals, Inc.
Vitae Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the structure-based discovery and development of molecule compounds for the treatment of chronic kidney disease, diabetes, Alzheimer’s disease, and atherosclerosis. Its lead product is VTP-27999, a renin inhibitor that offers renal protection in patients suffering from chronic kidney disease. The company also focuses on developing 11ß-HSD-1 inhibitor for the treatment of diabetes; beta-secretase inhibitor for the treatment of Alzheimer’s disease; and LXR modulator for the treatment of atherosclerosis. Vitae Pharmaceuticals, Inc. was formerly known as Concurrent Pharmaceuticals, Inc. and changed its name in Ma...
502 West Office Center Drive
Fort Washington, PA 19034
Founded in 2001
Key Executives for Vitae Pharmaceuticals, Inc.
Co-Founder and Member of The Scientific Advisory Board
Vice President of Discovery Biology
Compensation as of Fiscal Year 2013.
Vitae Pharmaceuticals, Inc. Key Developments
Vitae Pharmaceuticals, Inc. Presents at Boston Biotech Conferences LLC's The New York CEO Conference, Nov-13-2013 08:45 AM
Oct 29 13
Vitae Pharmaceuticals, Inc. Presents at Boston Biotech Conferences LLC's The New York CEO Conference, Nov-13-2013 08:45 AM. Venue: Apella, 450 East 29th Street, New York, NY 10016, United States. Speakers: Jeffrey S. Hatfield, Chief Executive Officer, President and Director.
Vitae Pharmaceuticals, Inc. Presents at Windhover's Therapeutic Area Partnerships Conference, Nov-29-2012 04:20 PM
Nov 26 12
Vitae Pharmaceuticals, Inc. Presents at Windhover's Therapeutic Area Partnerships Conference, Nov-29-2012 04:20 PM. Venue: Westin Copley Place, Boston, Massachusetts, United States.
Vitae Pharmaceuticals, Inc. Announces Promising Data for VTP-4, Drug Candidate Advancing toward Clinical Testing for the Treatment of Atherosclerosis
Sep 6 12
Vitae Pharmaceuticals, Inc. announced the presentation of promising preclinical in vivo data for the company's Liver X Receptor (LXR) modulator, VTP-4, being studied for the treatment of atherosclerosis. VTP-4 is a potent and selective modulator of LXR, activation of which has been shown to stimulate reverse cholesterol transport (RCT), to decrease vascular inflammation and to provide protection in several in vivo models of atherosclerosis. Results from multiple studies and in multiple animal species demonstrate that oral administration of VTP-4 leads to significant, dose dependent increases in key biomarkers of reverse cholesterol transport (RCT). In mice, administration of VTP-4 resulted in significant increases of the ABCA1 biomarker with all doses tested. In another mouse study, VTP-4 showed significant increases in reverse cholesterol transport and cholesterol excretion compared to vehicle. In primates, VTP-4 demonstrated strong induction of RCT biomarkers at all doses tested.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|